Article Text

Download PDFPDF
083 Intravenous magnesium for acute presentations of migraine to A&E
  1. Raphael Laurente,
  2. Isaiah See,
  3. Charlie Lane,
  4. Ali Alim-Marvasti,
  5. Michelle Balaratnam,
  6. Arvind Chandratheva,
  7. Manjit Matharu,
  8. Robert Simister,
  9. Salwa Kamourieh,
  10. Salman Haider
  1. University College London Hospitals NHS Foundation Trust


Background and aim Studies have demonstrated the role of magnesium on acute migraine attacks and prophylaxis via voltage-dependent blockade of N-methyl-D-aspartate (NMDA)-coupled channels. Our aim was to study the tolerability of intravenous (IV) magnesium in the treatment of migraine in the Emergency Department (ED) and the Same Day Emergency Care (SDEC) unit of University College Hospital, London.

Methods We performed a non-randomised open-label trial to establish the safety of IV magnesium sulfate. Patients were recruited from the ED or the SDEC unit of the hospital after being reviewed by consultant Neurologists from Aug 2021 – Jan 2022. Magnesium levels were measured prior to administration of the drug and complications were closely monitored.

Results 35 patients with status migrainosus were recruited; 30 were females and their mean age was 39 years (SD: 13.5 in years). All had normal serum magnesium levels prior to drug administration. No ECG changes were identified. None developed serious adverse symptoms during or immediately after infusion. A beneficial effect was noted in 15 patients, no effect in 10, and missing data in 10.

Conclusion Administration of IV Magnesium is an effective and tolerated adjunct for the management of migraine. Efficacy studies are currently underway.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.